CEO, CFO, others buying at Critical Outcome (V:COT)

John C. Drake, a Senior Officer and 10% Holder, acquired 86,207 Common Shares at a price of $1.160 and 86,207 Warrants exercisable at $1.210 for a period of 12 months on a direct ownership basis through a prospectus or prospectus exempt offering on September 19th, 2017. This represents a $100,000 investment into the company's shares and an account share holdings change of 25.7%.

Under the same terms:

Alison Silva, CEO and Director, acquired 43,100 Common Shares and 43,100 Warrants on a direct ownership basis through a prospectus or prospectus exempt offering on September 19th, 2017. This represents a $49,996 investment into the company's shares and an account share holdings change of greater than 100%.

Douglas Stewart Alexander, a Director, acquired 13,000 Common Shares and 13,000 Warrants on a direct ownership basis through a prospectus or prospectus exempt offering on September 19th, 2017. This represents a $15,080 investment into the company's shares and an account share holdings change of 78.1%.

Eugene Francis Kelly, CFO, acquired 8,600 Common Shares and 8,600 Warrants on a direct ownership basis through a prospectus or prospectus exempt offering on September 19th, 2017. This represents a $9,976 investment into the company's shares and an account share holdings change of 34.5%.

Bruno Maruzzo, a Director, acquired 4,400 Common Shares and 4,400 Warrants on a direct ownership basis through a prospectus or prospectus exempt offering on September 19th, 2017. This represents a $5,104 investment into the company's shares and an account share holdings change of 16.1%.

Heung-Joon (John) Yoo, a Director, acquired 4,400 Common Shares and 4,400 Warrants on a direct ownership basis through a prospectus or prospectus exempt offering on September 19th, 2017. This represents a $5,104 investment into the company's shares and an account share holdings change of 73.7%.

Critical Outcome is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Critical Outcome Technologies Inc. (COTI) is a clinical-stage biopharmaceutical company. The Company is engaged in drug discovery and development. The Company uses machine learning to develop targeted therapies thereby managing the timeline and cost of getting new drug therapies to market. The Company's artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds with a high probability of being developed from disease specific drug discovery through chemical optimization and preclinical testing. The CHEMSAS platform technology is designed for small molecules, and as a drug candidate discovery engine can be applied to any disease target with information for the target of interest. The Company's initial focus is in advancing the treatment of cancer with the Company's lead compound, COTI-2, having a p53-dependent mechanism of action demonstrating selective and potent anti- cancer activity.